Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial | Zendy

Geert H. Groeneveld | Zendy; Tanny J van der Reyden | Zendy; Simone A. Joosten | Zendy; Hester J. Bootsma | Zendy; Christa M. Cobbaert | Zendy; Jutte J.C. de Vries | Zendy; Ed J. Kuijper | Zendy; Jaap T. van Dissel | Zendy

Open Access

Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial

Author(s) -

Geert H. Groeneveld,

Tanny J van der Reyden,

Simone A. Joosten,

Hester J. Bootsma,

Christa M. Cobbaert,

Jutte J.C. de Vries,

Ed J. Kuijper,

Jaap T. van Dissel

Publication year - 2019

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkz207

Subject(s) - pneumococcal pneumonia , pneumonia , antibiotics , medicine , rifampicin , community acquired pneumonia , immunology , streptococcus pneumoniae , lipoteichoic acid , bacterial pneumonia , microbiology and biotechnology , staphylococcus aureus , biology , bacteria , genetics

The inflammatory response in pneumococcal infection is primarily driven by immunoreactive bacterial cell wall components [lipoteichoic acid (LTA)]. An acute release of these components occurs when pneumococcal infection is treated with β-lactam antibiotics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research